Elzbieta Sawicka

TL;DR: Treatment of mice with SRP299, a killed Mycobacterium vaccae-suspension gives rise to allergen-specific CD4+CD45RBLo regulatory T cells, which confer protection against airway inflammation and may have an essential role in restoring the balance of the immune system to prevent and treat allergic diseases.

TL;DR: The inhibitory effect of FTY720 on airway inflammation, induction of bronchial hyperresponsiveness, and goblet cell hyperplasia could be confirmed in an actively Ag-sensitized murine asthma model, clearly indicating that Th2 cell-driven allergic diseases such as asthma could benefit from such treatment.

TL;DR: Analysis of the functional response of FTY720-treated CD4+/CD25+ T cells revealed an increased suppressive activity in an in vitro Ag-specific proliferation assay, which correlated with enhanced function in vivo, with T-regulatory cells obtained from FTY 720-treated mice being able to suppress OVA-induced airway inflammation.

TL;DR: Allergen‐specific Tc2 cells respond to inhaled soluble antigen, produce an inflammatory response qualitatively similar to Th2 cells and therefore may exacerbate the Th2‐driven airway inflammation in asthma.

TL;DR: The profound dependency of eosinophils on PI3Kγ for pulmonary influx identifies this lipid kinase as an attractive target for the pharmacological intervention of asthma.